Novel predictive factor for lung cancer SBRT radiation pneumonitis risk and construction method of novel predictive factor

Abstract

The invention belongs to the field of disease risk prediction, and relates to a construction and verification method of a novel predictive factor for lung cancer stereotactic radiotherapy radiation pneumonitis risk, which comprises the following steps: A, case collection; b, performing 4DCT simulation positioning scanning; c, sketching a target region and an organ at risk; d, designing a radiotherapy plan; e, extracting tumor related parameters; f, calculating the occurrence probability of the concurrent radiation pneumonitis; g, screening predictive factors; and H, obtaining an intercept point. According to the invention, a novel predictive factor Lung / PTVL which has the highest correlation with RP greater than or equal to 2 in lung cancer SBRT treatment is screened out by using a radioactive biological model for the first time; the intercept point value of the novel predictive factor is obtained for the first time. The novel predictive factor can help clinicians to distinguish patients with high and low RP occurrence risks greater than or equal to 2 levels, and the clinicians can adopt appropriate treatment strategies according to the RP occurrence risks of the patients, so that the RP occurrence probability is reduced, and individualized precise radiotherapy is realized.

Description

technical field [0001] The invention belongs to the field of disease risk predictor screening, and relates to a predictor and a construction method for predicting the risk of radiation pneumonitis complicated by SBRT treatment. Background technique [0002] Primary lung cancer is one of the most common malignant tumors in my country. According to data released by the National Cancer Center in 2019, there were about 787,000 new cases of lung cancer in my country in 2015, with an incidence rate of 57.26 / 100,000, ranking first among malignant tumors in my country. Incidence first. For patients with stage I non-small cell lung cancer (NSCLC), radical surgical resection is the preferred treatment method, but for patients who cannot tolerate surgery due to age and other reasons (such as poor cardiopulmonary function, severe diabetes, etc.), stereo Stereotactic radiation therapy (SBRT) is the primary treatment of choice. The technology is characterized by concentrating the high-do...

AI Technical Summary

Problems solved by technology

[0004] In view of the fact that there is no easy to obtain and can accurately predict the occurrence probability of RP in lung cancer SBRT treatment in the world, the present invention proposes a new type of radiation pneumonitis predictor after stereotaxic treatment of lung cancer based on radiobiology model calculation, which can be used when radiotherapy planning is completed. Evaluate the risk of radiation pneumonitis in advance, adjust the treatment strategy according to the probability of risk, in order to reduce the probability of RP after SBRT treatment for lung cancer, and realize the individualized precise treatment of lung cancer SBRT

Images